James Mackay, PhD, joins Neomatrix Therapeutics, Inc. as Chief Business Advisor

Experienced Business Advisor who has led several therapeutics to market joins NeoMatrix Therapeutics, Inc.

April 18, 2025 — NeoMatrix Therapeutics, Inc. is pleased to announce that James Mackay, PhD has joined the company as its Chief Business Advisor. He is Founder and CEO of Kateran Consulting.

Dr. Mackay has over 25 years of development and commercialization expertise in the pharmaceutical industry, including 6 drug product approvals across multiple therapeutic areas. He held senior executive positions at AstraZeneca where he led the development and commercialization of drugs across a range of therapy areas and managed significant global functional departments. James is an independent Board member for MatriSys BioScience, Privo Technologies, Curadh MTR, Venquis Therapeutics, Nuvig Therapeutics and Resolute Science and is an advisor to a range of other pre-clinical and clinical stage biotechs. Additionally, James plays a pivotal role in the San Diego Ecosystem and currently sits on the Board and Executive Committee of CONNECT and was previously Vice-Chair and Chair of CONNECT. He also sits on the Board of BIOCOM, is a former Board member of the San Diego Economic Development Corporation (EDC) and is involved with Life Science Cares – San Diego and SD2. 

James holds a B.S. in Genetics and PhD in Medical Genetics from Aberdeen University, Scotland.

NeoMatrix Therapeutics, Inc. believes the addition of Dr. Mackay to its team will bolster its success now and in the future.

Contact:

Richard A. Clark, M.D., President & Chief Scientific Officer raclark@neomatrixtx.com.